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Abstract
Hypophysitis is the acute or chronic inflammation of the pituitary gland. The spectrum of hypophysitis has
expanded in recent years with the addition of two histologic subtypes and recognition as a complication of
treatment with immune checkpoint inhibitors. Despite the increased number of published cases, the pathogenesis
of hypophysitis is poorly understood, and treatment strategies are diverse and controversial. The diagnosis of
hypophysitis generally requires histopathologic confirmation. The presentation and clinical course of hypophysitis
varies. Hypophysitis can resolve spontaneously, relapse may occur, and some cases can be refractory to treatment.
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Background
Hypophysitis has gained greater clinical recognition over
time. Several histologic variants and causative agents
have been identified. Although hypophysitis remains a
rare diagnosis, the number of published cases has in-
creased substantially and expanded to involve a more
gender and age diverse population. The quantity and
quality of available information is limited, however, and
consensus, especially regarding treatment, has been elu-
sive. Prospective studies are necessary to better define
optimal diagnostic and management strategies.
Hypophysitis can be classified according to etiology,
morphology, and/or histopathology. Etiology refers to
primary or secondary cases of hypophysitis. Primary
hypophysitis refers to isolated inflammation of the pituit-
ary not associated with medications, systemic inflamma-
tory disorders, infections, or other diseases. Secondary
hypophysitis includes cases associated with immunother-
apy (interleukin 2, interferon, and medications targeting
cytotoxic T-lymphocyte antigen-4 [CTLA-4] or pro-
grammed cell death 1 [PD-1]) [1–6], rupture of sellar cysts
(Rathke’s cleft cysts and craniopharyngiomas), and rarely,
pituitary adenomas [7–15]. Some authors utilize the
term secondary hypophysitis more broadly and also
include systemic inflammatory processes which may
involve the pituitary gland (such as sarcoidosis, Wegener’s
granulomatosis, Crohn’s disease, Takayasu’s arteritis,
Cogan’s syndrome), inflammatory cell proliferative
disorders (Langerhans cell histiocytosis [LCH] and
Erdheim-Chester disease [ECD]), infections (tubercu-
losis, syphilis, Whipple’s disease, mycoses), and
tumor-associated inflammatory infiltrate (germinoma).
Morphologic categorization is made according to
whether inflammation involves the anterior pituitary gland
(adenohypophysitis), posterior gland and stalk (infundibu-
loneurohypophystis), or entire gland (panhypophysitis).
Histologic subtypes of hypophysitis include the follow-
ing: lymphocytic, granulomatous, xanthomatous, and
plasmacytic (Table 1). Occasionally, mixed histology is
encountered [16]. Necrotizing hypophysitis has also been
proposed as an additional variant, but it has only been
reported in 3 cases [17, 18]. Lymphocytic hypophysitis is
characterized by diffuse lymphocyte infiltration (primar-
ily T cells) of the pituitary gland. Lymphoid follicles can
be observed and occasional plasma cells, eosinophils,
and fibroblasts may also be present [19]. Granulomatous
hypophysitis shows large numbers of multinucleated
giant cells and histiocytes with granuloma formation
[20, 21]. Xanthomatous hypophysitis demonstrates
lipid-laden “foamy” histiocytes without the presence of
granulomas [22, 23]. Plasmacytic hypophysitis, also
termed IgG4-related hypophysitis, has extensive gland
infiltration by plasma cells with a high degree of IgG4
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positivity [24–26]. Pituitary gland fibrosis and atrophy
may occur in later stages of these hypophysitis variants.
Precise usage of the term hypophysitis is important.
Loose or inconsistent application (such as grouping ger-
minoma-associated inflammation and primary lympho-
cytic hypophysitis) can cause reader confusion and
suggest inappropriate treatments rather than provide diag-
nostic clarification. Unfortunately, such cases have been
mixed with primary hypophysitis in some review paper
data sets [27]. Unless otherwise stated, further discussion
in this manuscript will focus on patients with primary
hypophysitis. A caveat exists for IgG4-related hypophysi-
tis, which is often a manifestation of systemic disease with
involvement of multiple organs. Most authors have not
grouped IgG4-related hypophysitis in the general category
of secondary hypophysitis, though it may be reasonable to
do so. This manuscript does include an examination of
IgG4-related hypophysitis. Given the expanding applica-
tions of immune checkpoint inhibitors and increasing fre-
quency of this form of secondary hypophysitis, brief
discussion will also be devoted to immunotherapy-
associated hypophysitis.
Epidemiology
The annual incidence of hypophysitis is estimated to be
1 in 7–9 million. Hypophysitis accounts for approxi-
mately 0.4 % of pituitary surgery cases (based on a group
of large surgical series totaling nearly 10,000 procedures
at 5 centers) [28–32].
Lymphocytic hypophysitis was first reported in 1962
[33], and granulomatous hypophysitis was described in
the early twentieth century [34, 35]. The first cases of
xanthomatous hypophysitis and IgG4-related hypophysi-
tis were published more recently in 1998 and 2004, re-
spectively [22, 36].
Lymphocytic hypophysitis is the most common histo-
logic variant, with over 390 cases reported. Granuloma-
tous hypophysitis is the next most frequent subtype,
followed by xanthomatous and IgG4-related hypophysi-
tis [25]. Lymphocytic hypophysitis was initially thought
to occur only in adult women, but cases were
subsequently described in men [37] and children [38–
40]. Lymphocytic hypophysitis does occur more fre-
quently in women compared to men (approximately 3:1
ratio of cases [27]), in large part because of its associ-
ation with pregnancy [41]. Though recent series have
not shown as strong a relationship [42, 43], the majority
of cases among reproductive-aged women appear to
occur during the end of pregnancy or the first few
months after delivery [16, 27]. The incidence of lympho-
cytic hypophysitis peaks during the fourth decade of life
and is uncommon in children and the elderly.
Granulomatous and xanthomatous hypophysitis also
occur more frequently in women (approximately 3:1
ratio of cases), but neither form is linked with preg-
nancy. Xanthomatous hypophysitis and lymphocytic
hypophysitis have a similar mean age of presentation,
but granulomatous hypophysitis is diagnosed more
often at a slightly later timepoint in the fifth decade
[20, 23]. IgG4-related hypophysitis occurs more fre-
quently in men and tends to develop at a more ad-
vanced age in the seventh decade of life. IgG4-related
hypophysitis also does not have an association with
pregnancy [25, 26].
Immunotherapy-associated hypophysitis occurs in up
to 10–15 % of patients receiving agents targeting CTLA-
4, on average 2–3 months after starting therapy. Older
age and male gender may be risk factors for the develop-
ment of hypophysitis with anti-CTLA-4 medications.
Hypophysitis is comparatively rare following treatment
with anti-PD-1 agents. Hypophysitis has also been re-
ported very rarely after treatment with interleukin 2 and
interferon [6].
Clinical presentation
Patients with hypophysitis present with symptoms re-
lated to mass effect from pituitary gland enlargement
and pituitary/hypothalamic dysfunction. Headache is the
most common presenting symptom, occurring in about
half of patients. Visual symptoms due to compression of
the optic nerves and/or cranial nerves III, IV, and VI in
the cavernous sinuses can occur in a substantial mi-
nority of patients [16, 27, 42]. Cavernous carotid ar-
tery occlusion is a rare complication of hypophysitis
[31, 44–46]. The onset of symptoms, including headache,
can be insidious, subacute, or acute even mimicking apo-
plexy [42, 47, 48].
The majority of patients with hypophysitis have mul-
tiple anterior pituitary hormone deficiencies, and anter-
ior panhypopituitarism is not uncommon. The severity
of hormone deficiencies may appear to be out of propor-
tion to radiographic findings. Serum prolactin levels may
be low, normal, or elevated [16, 19, 27, 42]. Unlike what
is observed in clinically nonfunctioning pituitary adenomas
[49], there is not a clear hierarchy of anterior pituitary








Lymphocytic Female, ~3:1 Yes 4th decade
Granulomatous Female, ~3:1 No 5th decade
Xanthomatous Female, ~3:1 No 4th decade
Plasmacytic
(IgG4-related)
Male, ~2:1 No 7th decade
Mixed histology is observed occasionally, and necrotizing hypophysitis has
been proposed as an additional category. Data abstracted from references
[20, 23, 25, 27, 66]
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hormone deficiencies in hypophysitis patients. Hypothal-
amic pituitary adrenal axis dysfunction is frequently
present. Diabetes insipidus is also common and may occur
in up to half of patients [16, 19, 27, 42].
Immunotherapy-associated hypophysitis often presents
with headache and anterior hypopituitarism. The degree
of pituitary enlargement is typically mild, and compres-
sion of the optic apparatus is very rare. Unlike other
forms of hypophysitis, diabetes insipidus is extremely
unusual in patients with immunotherapy-associated
hypophysitis [6].
Diagnosis
The differential diagnosis for primary hypophysitis is
broad, and ultimately histopathology (which is not
always possible to obtain) is required for confirmation.
Alternative diagnostic considerations include anatomic
variants (a small/narrow sella turcica with specious pitu-
itary enlargement) and congenital malformations, pituit-
ary hyperplasia, solid and cystic sellar/suprasellar lesions
(such as pituitary adenomas with or without apoplexy,
Rathke’s cleft cyst, craniopharyngioma, pituitcyte-derived
tumors, hamartoma, dermoid or epidermoid cyst, gang-
liocytoma, lipoma), malignancies (central nervous sys-
tem germinoma, lymphoma, glioma, metastatic lesions,
LCH, ECD), systemic inflammatory disorders (sarcoidosis,
Wegener’s granulomatosis, Crohn’s disease, Takayasu’s ar-
teritis, Cogan’s syndrome), and infections (tuberculosis,
syphilis, Whipple’s disease, mycoses). A thorough evalu-
ation is necessary to accurately diagnose hypophysitis,
especially in the absence of tissue confirmation. In the lar-
gest series of pituitary stalk lesions published to date, only
4 % of pathology-proven diagnoses represented primary
hypophysitis (and only one-third of cases were inflamma-
tory disorders of any type). Significantly, more than half of
the confirmed stalk lesions represented neoplastic pro-
cesses, and half of these cases were metastatic lesions [50].
A positive response to glucocorticoids, often interpreted
as supporting evidence for hypophysitis, is not specific for
inflammatory processes. Glucocorticoids are part of stand-
ard treatment regimens for LCH and ECD [51, 52], and
temporary treatment responses can be observed in lymph-
oma and intracranial germinomas [53–55]. Treatment re-
sponses in the latter are likely due to effects on tumor
infiltrating lymphocytes. This lymphoid infiltrate can be
significant enough that misdiagnosis can even occur after
tissue biopsy due to sampling error [56–58].
Certain radiology findings may support a diagnosis
of hypophysitis. These imaging characteristics include
homogenous enhancement of the pituitary, diffuse sym-
metric gland enlargement, midline stalk thickening, ab-
sence of a posterior pituitary bright spot, normal sellar
size, dural thickening, parasellar T2-weighted hypointen-
sity, and parasellar mucosal thickening. One group
described a radiologic scoring model with an apparent
high ability to distinguish hypophysitis from pituitary ad-
enomas [59]. This model was not assessed for its discrim-
inatory value against other potential diagnoses. Ultimately,
radiologic findings are not specific for hypophysitis, espe-
cially compared to nonadenomatous sellar lesions.
Diagnostic criteria have been proposed for IgG4-related
hypophysitis. These include the following: 1) pituitary
histopathology demonstrating mononuclear infiltration
with greater than 10 IgG4-positive cells per high-
powered field, 2) magnetic resonance imaging (MRI)
showing a sellar mass and/or stalk thickening plus
biopsy-proven IgG4-related disease at another tissue
site, or 3) sellar mass and/or stalk thickening plus a
serum IgG4 level > 140 mg/dl and a radiologic and
clinical response to treatment with glucocorticoids
[24]. These proposed criteria may be inadequate in
some circumstances. Recent studies have shown that
neither serum IgG4 levels [60, 61] nor IgG4-positive
tissue staining [62–65] are necessarily sensitive nor
specific for IgG4-related disease. According to more
recent international consensus criteria, diagnoses of
IgG4-related disease are primarily based upon path-
ology demonstrating 2 of 3 major histopathological
features (dense lymphoplasmacytic infiltrate, storiform
fibrosis [a cartwheel or whirled pattern of fibrosis, at
least focally], and obliterative phlebitis) with appropri-
ate clinicopathologic correlation. IgG4 serum levels
and tissue staining have important secondary roles
[66]. Published cases of IgG4-related hypophysitis typ-
ically do not comment on the presence or absence of
such histologic features [26]. When it is described,
storiform fibrosis has been reported in some [67] but
not all cases of IgG4-related hypophysitis [68] follow-
ing tissue analysis. Obliterative phlebitis has not been
reported in any case of IgG4-related hypophysitis. As
Ngaosuwan et al. noted, the diagnosis of IgG4-related
hypophysitis is difficult without the presence of other
organ involvement [69]. Although only a minority of
reported IgG4-related hypophysitis cases have in-
cluded histopathology, almost all patients had other
organ involvement [70].
No case of immunotherapy-associated hypophysitis
has been confirmed by pituitary gland biopsy. Diagnoses
are established clinically based upon the close temporal
relationship of immunotherapy treatment and the devel-
opment of hypopituitarism with reversible pituitary
enlargement [6, 71]. The relationship of lymphocytic
hypophysitis with pregnancy [27, 41] may also allow a
clinical diagnosis to be made with a reasonable degree of
confidence in some pregnant or early postpartum
women without tissue confirmation when appropriate
imaging and biochemical findings are present with an
otherwise negative thorough diagnostic evaluation.
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Patient demographics and coexistent medical conditions
may also help focus diagnostic considerations. For ex-
ample, intracranial germinomas have a peak incidence in
the second decade of life and are extremely rare after
the age of 30 [72]. LCH can be diagnosed at any age, but
the incidence of this disease progressively declines
throughout life [73, 74].
Given the broad differential diagnosis for hypophysitis,
caution and close follow up is strongly advised for the
treatment of presumed cases lacking histopathologic
confirmation.
Treatment
No prospective controlled studies have examined the
treatment of hypophysitis, and a limited number of cases
detail the natural history of untreated disease. Available
retrospective data sets are confounded by reporting and
treatment selection biases and likely encompass a het-
erogeneous group of diseases due to the lack of histo-
logic confirmation in many cases and variable clinical
evaluation. Medical therapies differ significantly by the
type of agent, dosage, and duration of treatment.
Symptoms from mass effect, such as optic nerve com-
pression and other cranial nerve palsies, and severe
headache are general indications for the treatment of
hypophysitis (Fig. 1). Practice patterns vary for less
clinically severe cases. It is unclear whether treatment
with immune suppressing medications improves pituit-
ary function outcomes compared to supportive therapy.
Spontaneous resolution of pituitary enlargement has
been observed in a number of published cases of hypo-
physitis [19]. One group recently reported regression of
radiologic findings in 15/15 patients receiving supportive
therapy [43]. A large recent retrospective review of
hypophysitis cases in Germany noted radiologic improve-
ment or stability in 16/22 cases without active treatment
[75]. Pituitary surgery (gross total resection or partial
resection) and glucocorticoid therapy appeared to be
somewhat more effective at mass reduction in that study.
Surgery (generally patients undergoing gross total resec-
tion) was associated with less improvement and greater
loss of pituitary function. Patients receiving glucocorticoid
therapy had a significant risk of relapsing pituitary en-
largement and experienced frequent side effects from
treatment. Approximately one-quarter of patients receiv-
ing supportive therapy demonstrated improvement in pi-
tuitary function, and 82 % of that group had stable or
improved function. Similar results were reported in the
patients treated with pharmacologic doses of glucocorti-
coids. Headache resolution was similar in all three groups
[75]. Comparable rates of pituitary function recovery were
reported following supportive therapy by Khare et al. [43].
A review by Lupi et al. suggested that pituitary function
improvement may occur in approximately one-half of pa-
tients treated with glucocorticoids. Importantly, histopath-
ology was available in only 22 % of these patients [76].
Similarly, a minority of patients had tissue confirmation in
the study from Germany. Moreover, evaluation for sec-
ondary causes of hypophysitis was limited in the majority
of those patients [42, 75]. Limited clinical evaluations were
also frequent in the largest review of granulomatous hypo-
physitis cases [20].
Other immunosuppressive agents such as metho-
trexate, azathioprine, rituximab, infliximab, cyclospor-
ine, and mycophenolate mofetil have been utilized in
a small number of patients with hypophysitis [75–82].
Treatment with stereotactic radiosurgery and fraction-
ated radiotherapy has been reported in a few patients,
typically with refractory disease. Radiation dosages
ranged from low levels to higher amounts used to
treat pituitary adenomas [31, 83, 84].
Patients with immunotherapy-associated hypophysitis
have been treated with physiologic to high-dose gluco-
corticoids. Although it is unclear whether pharmacologic
Fig. 1 Hypophysitis was diagnosed in a 30 year old during the late third trimester of pregnancy. The patient presented with 3 weeks of progression
vision loss. Panel a depicts a coronal pre-contrast T1-weighted image of the pituitary. Transsphenoidal biopsy (Panel b) demonstrated lymphocytic
hypophysitis and glucocorticoid therapy was begun with prednisone 60 mg daily. Following delivery, the pituitary gland decreased in size (Panel c)
and remained stable 2 months (Panel d) and 5 months (Panel e) after glucocorticoid taper and discontinuation
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dosages of glucocorticoids improve patient outcomes,
higher doses do not appear to negatively impact the anti-
tumor efficacy of immunotherapy or patient survival [6].
Improvement of pituitary function occurs in some pa-
tients following the resolution of hypophysitis; thyroidal
and gonadal axis normalization occurs more frequently
than adrenal recovery. The development of hypophysitis
may be associated with improved patient survival in mel-
anoma patients treated with Ipilimumab [71, 85].
Pathogenesis
The mechanisms underlying the development of hypo-
physitis are unknown. Other autoimmune diseases coex-
ist in a portion of patients with hypophysitis. Unlike
many of these other conditions, pituitary autoantigens in
hypophysitis have not yet been clearly identified. Several
candidates have been proposed, including growth hor-
mone, pituitary gland specific factors 1a and 2 [86, 87],
alpha-enolase and gamma-enolase [88, 89], secretogran-
nin II [90], chorionic somatomammotropin, CGI-99 [91],
and corticotroph-specific transcription factor [92]. Mea-
surements of antibodies to these proteins, however, do not
have sufficient sensitivity and specificity to be diagnostic-
ally useful [16, 93]. Given the lack of clinically validated
autoantigens, many studies have utilized indirect im-
munofluorescence (IIF) to detect the presence of pituitary
autoantibodies. Ricciuti et al. systematically described
methodologic limitations of IIF in the assessment of anti-
pituitary antibodies, their potential effects on data inter-
pretation, and methods to optimize results [94].
The pathogenic role of IgG4 in IgG4-related disease,
including hypophysitis, is unclear, and it has been sug-
gested that elevation of these antibodies may represent a
bystander phenomenon [95]. IgG4 predominance often
correlates with immune downregulation, in part due to
its ability to participate in fragment antigen binding arm
exchange [96].
Immunotherapy agents presumably can activate an
autoimmune process directed against unidentified pituit-
ary antigens. Pituitary autoantibodies were detected in
patients who developed hypophysitis following treatment
with Ipilimumab (a monoclonal antibody targeting
CTLA-4), but these antibodies were not present in pa-
tients without hypophysitis. CTLA-4 is also expressed by
the pituitary gland, and treatment with Ipilimumab may
directly target pituitary cells via activation of the clas-
sical complement pathway and antibody-dependent
cell-mediated cytotoxicity (ADCC) [97–99]. Pituitary
CTLA-4 expression levels appear to vary widely [100]
and may affect the risk of developing hypophysitis fol-
lowing treatment with Ipilimumab. In support of this
hypothesis, hypophysitis has not been reported in pa-
tients with germline CTLA-4 mutations, although
many of these patients had other severe autoimmune
diseases which can occur following treatment with Ipi-
limumab [101, 102]. It is unknown whether PD-1 is
expressed by the pituitary gland. Notably, anti-PD-1
agents are IgG4-based antibodies, which can not acti-
vate the classical complement pathway and are not ef-
fective mediators for ADCC [96, 103–105].
Conclusions
Currently, the diagnosis of primary hypophysitis typically
requires a thorough evaluation for other potential neo-
plastic lesions, infiltrative diseases, infection, and systemic
inflammatory processes plus histopathologic confirmation.
In some cases, tissue biopsy may not be feasible. Cases of
immunotherapy-associated hypophysitis and lymphocytic
hypophysitis associated with pregnancy may potentially be
diagnosed with some degree of confidence without sur-
gery. Cranial nerve deficits due to mass effect from pituit-
ary gland enlargement and severe headache are general
indications for treatment with medical therapy and/or sur-
gery. It is unclear whether active treatment improves clin-
ical outcomes compared to supportive therapy for more
mild cases of hypophysitis, and the therapies may be asso-
ciated with side effects. Pituitary gland debulking rather
than gross total resection is more commonly performed.
Glucocorticoids (at variable dosages and duration) are the
most frequent choice for medical therapy, though many
other immunosuppressive agents have been utilized in the
treatment of hypophysitis. Even when treatment is initially
successful, disease recurrence is not uncommon. Radi-
ation therapy appears promising, especially for refractory
cases of hypophysitis, but the available published data
consists of only a handful of patients.
Hypophysitis is an increasingly recognized but rare and
poorly understood heterogeneous disease. The pathogen-
esis of primary hypophysitis is not yet known, and clinic-
ally validated disease markers have not been identified. In
the absence of more detailed knowledge, various etiologic,
morphologic, and histologic categories have been pro-
posed, but the clinical utility of such schemas is limited.
Inconsistent usage of terminology and variable diagnostic
evaluations have also clouded data interpretation. Avail-
able studies are largely limited to retrospective series that
likely include patients with diverse pathologies. Clinical
investigation is constrained by the rarity of the disease.
The acquisition of sufficient controlled prospective data
will require multicenter collaboration. Until such investi-
gations take place, optimal management strategies will
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